PHASE 2A OPEN-LABEL STUDY OF MT-3724, A NOVEL CD20-TARGETING ENGINEERED TOXIN BODY, IN COMBINATION WITH LENALIDOMIDE (LEN) IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
EHA Library, Roger Waltzman,
293750
REGN1979 INDUCES TRANSIENT INCREASE IN CYTOKINE LEVELS, T-CELL ACTIVATION, AND CIRCULATING T-CELL REDUCTION, BUT NO SUSTAINED EFFECTS ON T-CELLS OR CYTOKINE RELEASE
EHA Library, Jurriaan Brouwer-Visser,
293759
LOW PERCENTAGE OF T LYMPHOCYTES IN HODGKIN´S LYMPHOMA LYMPH NODES, MEASURED BY FLOW CYTOMETRY, HAS AN ADVERSE IMPACT ON PROGRESSION FREE SURVIVAL REGARDLESS OF NEGATIVE INTERIM PET SCAN STATUS.
EHA Library, Laura Korin,
293838
PRELIMINARY RESULTS OF RESPONSE-ADAPTED STUDY OF IBRUTINIB, TEMOZOLOMIDE, ETOPOSIDE, DOXIL, DEXAMETHASONE, AND RITUXIMAB (TEDDI-R) IN AGGRESSIVE B-CELL LYMPHOMAS WITH SECONDARY INVOLVEMENT OF THE CNS
EHA Library, Mark Roschewski,
293744
25 CASES OF NEUROLYMPHOMATOSIS, A SINGLE-INSTITUTION EXPERIENCE OVER 13 YEARS; CLINICAL FEATURES, DIAGNOSIS, AND PROGNOSIS
EHA Library, Kentaro Narita,
293766